港股上市公司中国抗体-B（03681）今日盘中股价大涨32.68%，引起市场广泛关注。截至下午1点51分，该股报价2.02港元。
消息面上，中国抗体近日宣布完成发行合共1.13亿股。公司此前公告称，拟向26名认购人发行约1.128亿股认购股份，占经扩大已发行股份约9.37%，每股认购价1.10港元，共募资约1.24亿港元。这一消息似乎成为推动股价上涨的主要因素。
根据公告，此次配售所得款项将用于以下几个方面：45%用于SM17的研发及临床项目以及潜在国际合作，特别是在中国进行特应性皮炎的皮下桥接研究及二期临床研究；20%用于目前不在公司产品线内的新候选药物的临床前研究、临床试验、相关生产及注册申报的准备工作，以使公司的产品组合多元化；剩余35%将用作一般营运资金。这一资金分配方案显示出公司在产品研发和业务扩张方面的积极布局，可能增强了投资者对公司未来发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.